HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Protalix BioTherapeutics (AMEX:PLX) with a Buy and maintains $12 price target.
A stock expert thinks Protalix is a good company and still believes it could reach $12 per share. This shows the expert hasn't changed their mind about the company's chances, which might mean they see steady progress ahead.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.